Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
03 2020
Historique:
received: 19 06 2019
revised: 11 09 2019
accepted: 15 09 2019
pubmed: 7 10 2019
medline: 6 5 2020
entrez: 7 10 2019
Statut: ppublish

Résumé

Standard treatment of early cervical cancer involves a radical hysterectomy and retroperitoneal lymph node dissection. The existing evidence on the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer is either nonrandomized or retrospective. The purpose of this study was to compare the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer. The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries randomly assigned 631 women with International Federation of Gynecology and Obstetrics 2009 stage IA1 with lymph-vascular invasion to IB1 cervical cancer to undergo minimally invasive (n = 319) or open radical hysterectomy (n = 312). The Laparoscopic Approach to Carcinoma of the Cervix trial was suspended for enrolment in September 2017 because of an increased risk of recurrence and death in the minimally invasive surgery group. Here we report on a secondary outcome measure: the incidence of intra- and postoperative adverse events within 6 months after surgery. Of 631 randomly assigned patients, 536 (85%; mean age, 46.0 years) met inclusion criteria for this analysis; 279 (52%) underwent minimally invasive radical hysterectomy, and 257 (48%) underwent open radical hysterectomy. Of those, 300 (56%), 91 (16.9%), and 69 (12.8%) experienced at least 1 grade ≥2 or ≥3 or a serious adverse event, respectively. The incidence of intraoperative grade ≥2 adverse events was 12% (34/279 patients) in the minimally invasive group vs 10% (26/257) in the open group (difference, 2.1%; 95% confidence interval, -3.3 to 7.4%; P=.45). The overall incidence of postoperative grade ≥2 adverse events was 54% (152/279 patients) in the minimally invasive group vs 48% (124/257) in the open group (difference, 6.2%; 95% confidence interval, -2.2 to 14.7%; P=.14). For early cervical cancer, the use of minimally invasive compared with open radical hysterectomy resulted in a similar overall incidence of intraoperative or postoperative adverse events.

Sections du résumé

BACKGROUND
Standard treatment of early cervical cancer involves a radical hysterectomy and retroperitoneal lymph node dissection. The existing evidence on the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer is either nonrandomized or retrospective.
OBJECTIVE
The purpose of this study was to compare the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer.
STUDY DESIGN
The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries randomly assigned 631 women with International Federation of Gynecology and Obstetrics 2009 stage IA1 with lymph-vascular invasion to IB1 cervical cancer to undergo minimally invasive (n = 319) or open radical hysterectomy (n = 312). The Laparoscopic Approach to Carcinoma of the Cervix trial was suspended for enrolment in September 2017 because of an increased risk of recurrence and death in the minimally invasive surgery group. Here we report on a secondary outcome measure: the incidence of intra- and postoperative adverse events within 6 months after surgery.
RESULTS
Of 631 randomly assigned patients, 536 (85%; mean age, 46.0 years) met inclusion criteria for this analysis; 279 (52%) underwent minimally invasive radical hysterectomy, and 257 (48%) underwent open radical hysterectomy. Of those, 300 (56%), 91 (16.9%), and 69 (12.8%) experienced at least 1 grade ≥2 or ≥3 or a serious adverse event, respectively. The incidence of intraoperative grade ≥2 adverse events was 12% (34/279 patients) in the minimally invasive group vs 10% (26/257) in the open group (difference, 2.1%; 95% confidence interval, -3.3 to 7.4%; P=.45). The overall incidence of postoperative grade ≥2 adverse events was 54% (152/279 patients) in the minimally invasive group vs 48% (124/257) in the open group (difference, 6.2%; 95% confidence interval, -2.2 to 14.7%; P=.14).
CONCLUSION
For early cervical cancer, the use of minimally invasive compared with open radical hysterectomy resulted in a similar overall incidence of intraoperative or postoperative adverse events.

Identifiants

pubmed: 31586602
pii: S0002-9378(19)31165-2
doi: 10.1016/j.ajog.2019.09.036
pmc: PMC7181470
mid: NIHMS1575970
pii:
doi:

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

249.e1-249.e10

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Références

Eur J Surg Oncol. 2017 Jun;43(6):994-1002
pubmed: 27546015
PLoS One. 2018 Mar 19;13(3):e0193033
pubmed: 29554090
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
J Laparoendosc Adv Surg Tech A. 2017 Nov;27(11):1132-1144
pubmed: 28300465
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Int J Med Robot. 2007 Sep;3(3):224-8
pubmed: 17924449
Gynecol Oncol. 2015 Aug;138(2):457-71
pubmed: 26056752
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
J Laparoendosc Adv Surg Tech A. 2015 Dec;25(12):990-8
pubmed: 26584414
Obstet Gynecol. 1974 Aug;44(2):265-72
pubmed: 4417035
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gynecol Oncol. 2007 Feb;104(2 Suppl 1):13-6
pubmed: 17157362
J Robot Surg. 2017 Mar;11(1):1-16
pubmed: 27424111
J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):584-8
pubmed: 18722970
Surg Clin North Am. 2001 Aug;81(4):815-28
pubmed: 11551127
BMC Cancer. 2015 Nov 24;15:928
pubmed: 26596955

Auteurs

Andreas Obermair (A)

Queensland Centre for Gynaecological Cancer Research, University of Queensland, Centre for Clinical Research, RBWH, Herston, QLD Australia. Electronic address: Obermair@powerup.com.au.

Rebecca Asher (R)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.

Rene Pareja (R)

Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá and Clínica de Oncología Astorga, Medellín, Colombia.

Michael Frumovitz (M)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Aldo Lopez (A)

Department of Gynecologic Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.

Renato Moretti-Marques (R)

Gynecologic Oncology Division, Oncologic Center, Hospital Israelita Albert Einstein, São Paulo-SP, Brazil.

Gabriel Rendon (G)

Instituto de Cancerologia-Las Americas, Medellín, Colombia.

Reitan Ribeiro (R)

Department of Surgery, Erasto Gaertner Hospital, Curitiba, Brazil.

Audrey Tsunoda (A)

Department of Surgery, Erasto Gaertner Hospital, Curitiba, Brazil.

Vanessa Behan (V)

Queensland Centre for Gynaecological Cancer Research, University of Queensland, Centre for Clinical Research, RBWH, Herston, QLD Australia.

Alessandro Buda (A)

Unit of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, San Gerardo Hospital, Monza MB, Italy.

Marcus Q Bernadini (MQ)

Department of Gynecologic Oncology, Princess Margaret Cancer Center, Ontario, Canada.

Hongqin Zhao (H)

Department of Gynecology, First Affiliated Hospital of Wenzhou Medical College, Ouhai, Wenzhou, China.

Marcelo Vieira (M)

Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil.

Joan Walker (J)

Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Norman, OK.

Nick M Spirtos (NM)

Division of Gynecologic Oncology, Women's Cancer Center of Nevada, LV.

Shuzhong Yao (S)

Department of Obstetrics and Gynecology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Naven Chetty (N)

Department of Gynecologic Oncology, Mater Health Services Brisbane, South Brisbane, QLD, Australia.

Tao Zhu (T)

Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

David Isla (D)

Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Mexico.

Mariano Tamura (M)

Gynecologic Oncology Division, Oncologic Center, Hospital Israelita Albert Einstein, São Paulo-SP, Brazil.

James Nicklin (J)

Department of Gynaecologic Oncology, Royal Brisbane and Women's Hospital and The University of Queensland, Brisbane, QLD, Australia.

Kristy P Robledo (KP)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.

Val Gebski (V)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.

Robert L Coleman (RL)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Gloria Salvo (G)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Pedro T Ramirez (PT)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH